Genentech   ACCES A Member of the Roche Group for Erivedge (vismodegib) capsule		escriber Servi		M-US-0	anning QR code quired Field (*) 00006688(v2.0) REQUESTED DOCUMENTS	
Save time by submitting this form online below: Quick Enroll NO ACCOUNT REQUIRED Questions? Call Access Solutions at (888) 249-4918						
Step 1 Patient Information						
Services Requested (Check all that apply):  *First name:  *Last name:    Benefits Investigation/ Prior Authorization  *Date of birth (MM/DD/YYYY):  /  Gender:  Male  Female    Street:						
		Primary Insurance	Secondary Insura	nce F	Pharmacy Benefit	
Insurance name						
Subscriber name (if not pat	ient)					
Subscriber/Policy ID #						
Group #						
Insurance phone						

Step 3

Erivedge® (vismodegib) Co-pay Program Enrollment

## □ By checking this box, I certify that:

- I have the patient's consent to enroll in the Genentech Oncology Co-Pay Assistance Program for assistance with drug out-of-pocket costs and / or Genentech Oncology administration out-of-pocket costs
- The patient is not using and you will not bill any federal or state-funded health care program. This includes, but is not limited to, Medicare, Medicaid, Medigap, VA, DoD and TRICARE
- The patient is not currently receiving Genentech Oncology drugs from the Genentech Patient Foundation
- The patient is not currently receiving assistance from any other charitable organization for any of their out-of-pocket costs that are covered by the Genentech Oncology Co-pay Program
- Genentech reserves the right to rescind, revoke or amend the program without notice at any time.
- I have read and accepted the full Program Terms and Conditions as found on the following link: go.gene.com/oncology

## Please continue to Step 4 on the next page

<sup>†</sup>National Provider Identifier.

Erivedge and the Access Solutions logo are registered trademarks of Genentech, Inc.

@ 2024 Genentech USA, Inc. So. San Francisco, CA All rights reserved. Printed in USA

Phone: (888) 249-4918 | Fax: (877) 313-2659 | Genentech-Access.com/Erivedge | M-US-00006688(v2.0) 03/24

Genentech   ACCESS >> SOLUTIONS°	Complete online by scanning QR code			
for <i>Erivedge</i> <sup>®</sup> Prescriber	Service Form	Required Field (*) M-US-00006688(v2.0) SUBMIT ONLY REQUESTED DOCUMENTS		
Step 4 Patient Information (pleas	e re-enter)			
*First name: *Last n	ame:	*DOB (MM/DD/YYYY): / /		
Step 5 Diagnosis and Clinical Info	ormation			
To the highest level of specificity, provide:	Has patient started therapy?	□ Yes □ No		
*Primary ICD-10 Code:	*Metastatic basal cell carcinor	*Metastatic basal cell carcinoma? 🗆 Yes 🗆 No		
Secondary ICD-10 Code:	Locally advanced basal cell c	*Locally advanced basal cell carcinoma recurred following surgery,		
Erivedge® (vismodegib) capsule 150 mg	or not a candidate for surge	or not a candidate for surgery, and not a candidate for radiation? $\square$ Yes $\square$ No		
□ 150 mg daily □ Other: Disper	nse:month supply	Refill times		
Pharmacy and Shipping Information:				
Specialty pharmacy: □ Yes □ No Preferred specialty	/ pharmacy:			
Onsite pharmacy: □ Yes □ No Onsite pharmacy:				
Ship to: 🛛 Patient 🗇 Practice 🗇 Other:				
Step 6 Prescriber Information				
*First name:	*Last name:	*Last name:		
*Practice name:				
*Street:	Suite:	*City:		
*State: *ZIP: Press	riber tax ID #:	Prescriber NPI <sup>+</sup> #:		
Group NPI <sup>+</sup> #: Office	e contact:	Contact email:		

If you are a resident of a US state that provides certain rights with respect to your personal information, a complete description of the personal information we may collect and process, the purposes for which it is used by Genentech, and your rights under your state's privacy laws concerning your personal information can be found in our privacy notice at <a href="https://www.gene.com/privacy-policy">https://www.gene.com/privacy-policy</a>

Contact fax: (

## Health Care Provider Certification

**By signing this form, I certify:** (a) The above therapy is medically necessary for this patient and the treatment decision has been made by the prescribing physician. (b) If the indication for which you are prescribing a Genentech product is not listed in the FDA-approved label, you are prescribing the medication for an "unapproved" use, meaning that the FDA has not approved the efficacy, dosage amount or safety of this medication for such a use. (c) I received the authorization to release the information above and other protected health information (as defined by the Health Insurance Portability and Accountability Act of 1996 [HIPAA]) to Genentech, Inc., Genentech Access Solutions, the contracted dispensing pharmacy, or other contractors for the purpose of requesting reimbursement support, assisting in initiating or continuing therapy, as a break in treatment would negatively impact the patient's therapeutic outcome and (d) I will not attempt to seek reimbursement for free product provided to the patient. I request Genentech Access Solutions convey to the pharmacy chosen by the above-named patient the prescription described herein. (e) The services you are requesting on behalf of the patient may include benefits investigation (BI), benefits re-verification, prior authorization support (PA), co-pay card and co-pay assistance foundation referral. In the absence of a checkbox selecting a service, we will perform BI/PA services on behalf of the patient. (f) No action on these services will be taken until the patient consent document has been received. (g) For prescribers in states with official prescription form requirements, such as New York, prescriptions must be submitted on an official state prescription pad along with this enrollment form.

Sign, date & fax to (877) 313-2659 \*Prescriber's Signature: \_\_\_\_\_\_ (Original or stamped signature required) \*Date: / /

<sup>†</sup>National Provider Identifier.

Contact phone: (

Step 7

Erivedge and the Access Solutions logo are registered trademarks of Genentech, Inc. © 2024 Genentech USA, Inc. So. San Francisco, CA All rights reserved. Printed in USA

Phone: (888) 249-4918 | Fax: (877) 313-2659 | Genentech-Access.com/Erivedge | M-US-00006688(v2.0) 03/24